Drug Trial Radar · NCT03177902
Evaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast Cancer
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Jun 4, 2017
Primary completion
Apr 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Bengbu Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 6, 2017
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 85 years
Summary
As written by the sponsor on the registry.
Breast cancer is one of the most common cancers in China. Even though advances in the field of breast cancer therapeutics, chemotherapy remains the mainstay therapeutic modality. The cytotoxic therapies are generally associated with some immediate or otherwise delayed side effects, such as adverse effects on gastrointestinal, hepatic, renal and hematological systems. The effect of chemotherapy on endocrine system, however, is comparatively less envisaged. Several epidemiological studies show a positive association between plasma thyroid hormones levels and breast cancer risk. Thyroid dysfunction is emerging as a variably common endocrine toxicity of several anticancer drugs. Due to the scarcity of data on the functioning of thyroid gland during chemotherapy in a large scale group, the present study was aimed to investigate the incidence of thyroid abnormity in Chinese women with newly diagnosed breast cancer, and also the effects of chemotherapy on thyroid gland functions or structure in these breast cancer patients undergoing at least four cycles of chemotherapy.
Conditions
- Breast Cancer Female
- Thyroid Gland
Interventions
ChemotherapyDrug
Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants newly diagnosed with breast cancerTime frame: 1 week around the indicated detection point
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.